Results: New fractures were found about 8% in the Aclasta group, and 13.6% in the Placebo group, statistical significance (p <0.001). Vertebral fractures different from Aclasta 1.3%; Placebo groups 3.7% and the incident femoral head fracture in turn is 2.6% and 3.7%.